Actively Recruiting
Adipose Tissue Gene Expression and Metabolomics Links to the Gut Microbiome-brain Axis
Led by Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta · Updated on 2026-03-31
100
Participants Needed
1
Research Sites
77 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to understand how adipose tissue (fat) and the gut microbiota (the bacteria in the gut) may influence brain function and cognition. It has been observed that changes in adipose tissue in animals such as mice and Drosophila (a type of insect) affect memory and other brain functions. Additionally, it is believed that the gut microbiota also plays an important role in cognition. This study will explore how gene expression in adipose tissue, blood metabolites, and the gut microbiota are related to cognitive function, such as memory and thinking, in individuals with and without obesity. The investigation will also assess whether these factors can predict changes in the brain over time and how they influence sleep, physical activity, and blood sugar regulation. Advanced technologies will be used to analyze samples of tissue, blood, and microbiota, with the goal of identifying new mechanisms through which obesity affects the brain. This research may contribute to the development of new diagnostic and therapeutic strategies for cognitive problems in individuals with obesity.
CONDITIONS
Official Title
Adipose Tissue Gene Expression and Metabolomics Links to the Gut Microbiome-brain Axis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women over 20 years old
- Scheduled for surgical intervention to extract adipose tissue
- Signed informed consent for study participation
You will not qualify if you...
- Not meeting inclusion criteria
- Non-obesity-related systemic diseases such as cancer, severe kidney or liver disease
- Systemic diseases with intrinsic inflammation like rheumatoid arthritis, Crohn's disease, asthma, chronic infections (HIV/tuberculosis), or any infectious disease
- Pregnant or breastfeeding women
- Persons under legal or administrative restrictions
- Infection symptoms in the past month
- Use of antibiotics, antifungals, or antivirals in the previous 3 months
- Chronic use of steroidal or anti-inflammatory drugs
- Major psychiatric history
- Excessive alcohol intake (over 40g/day for women, over 80g/day for men) or drug abuse
- Treatment with immunosuppressants
- Severe eating disorders
- Serum liver enzymes (GOT, GPT) above twice the upper limit of normal or signs of liver disease
- History of iron balance disorders like genetic hemochromatosis or hemosiderosis
- Creatinine level greater than 1.2 or glomerular filtration rate below 40
- Current treatment for malignant neoplasia except basal or squamous cell skin cancer
- Heart disease classified as class III or IV or known ischemic cardiovascular disease
- Renal failure, history of kidney transplant, or current dialysis treatment
- Chronic constipation with bowel movements less than once every 7 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut d'Investigació Biomèdica de Girona (IDIBGI)
Girona, Girona, Spain, 17007
Actively Recruiting
Research Team
J
José Manuel Fernández-Real, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here